SAILIFE Sai Life Q2 FY26 results (Jul–Sep 2025) and concall
Sai Life Sciences delivered a robust H1 FY26 performance characterized by significant revenue growth and margin expansion, primarily driven by the scaling of late-stage and commercial programs in the CDMO segment. The company is aggressively investing in capacity and new technology modalities like peptides, ADCs, and oligonucleotides to capitalize on the 'China+1' supply chain rebalancing trend. Management remains confident in sustaining high growth rates and improving profitability through operational efficiencies and asset productivity.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue up 35.6%, net profit up 100.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 396 | 440 | 580 | 496 | 537 +36% |
| EBITDA | 102 | 120 | 158 | 121 | 146 +43% |
| Net profit | 42 | 54 | 88 | 60 | 84 +100% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
